Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review.
Antineoplastic agents
Chemotherapy
Peritoneal dialysis
Safety
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
07
02
2020
revised:
26
03
2020
accepted:
26
03
2020
pubmed:
16
4
2020
medline:
17
6
2020
entrez:
16
4
2020
Statut:
ppublish
Résumé
There is no clear consensus on the administration of anti-neoplastic agents to patients on peritoneal dialysis. Dose adjustments to prevent serious adverse events are still not established. Thus, the aim of this study was to systematically review current evidence on the use of systemic oncology therapies in peritoneal dialysis. A systematic review was conducted using PubMed, Scopus, and Cochrane. All relevant data was collected, including clinical and pharmacokinetic parameters, with comparison to subjects with normal renal function. Sixteen studies were included. All were case reports. Eighteen types of anti-cancer drugs were reviewed. Multiple adverse events and altered pharmacokinetics were reported. Data concerning the use of anti-neoplastic drugs in patients on peritoneal dialysis are still sparse. The elimination of anti-cancer agents seems often altered in such patients, resulting in serious adverse events. Based on the available evidence, we suggest the need for dose adjustment of each drug.
Sections du résumé
BACKGROUND
BACKGROUND
There is no clear consensus on the administration of anti-neoplastic agents to patients on peritoneal dialysis. Dose adjustments to prevent serious adverse events are still not established. Thus, the aim of this study was to systematically review current evidence on the use of systemic oncology therapies in peritoneal dialysis.
METHODS
METHODS
A systematic review was conducted using PubMed, Scopus, and Cochrane. All relevant data was collected, including clinical and pharmacokinetic parameters, with comparison to subjects with normal renal function.
RESULTS
RESULTS
Sixteen studies were included. All were case reports. Eighteen types of anti-cancer drugs were reviewed. Multiple adverse events and altered pharmacokinetics were reported.
CONCLUSION
CONCLUSIONS
Data concerning the use of anti-neoplastic drugs in patients on peritoneal dialysis are still sparse. The elimination of anti-cancer agents seems often altered in such patients, resulting in serious adverse events. Based on the available evidence, we suggest the need for dose adjustment of each drug.
Identifiants
pubmed: 32294609
pii: S1040-8428(20)30085-8
doi: 10.1016/j.critrevonc.2020.102947
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102947Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.